Krystal Biotech, Inc. KRYS
Krystal Biotech, Inc. (Nasdaq: KRYS) is a dermatology drug developer. Its lead program, VYJUVEK (beremagene geperpavec-svdt), is in Phase 3 for Dystrophic epidermolysis bullosa (DEB). Its next catalyst on record is KB803: Last patient visit for IOLITE Phase 3 study with top-line results (February 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KB803 — Last patient visit for IOLITE Phase 3 study with top-line results (February 2027). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VYJUVEK (beremagene geperpavec-svdt) | Dystrophic epidermolysis bullosa (DEB) | gene therapy | Approved |
| KB111 | Dystrophic epidermolysis bullosa (wound healing) | gene therapy | Phase 3 |
| KB803 | Corneal abrasions in DEB patients | gene therapy | Phase 3 |
| KB707 (inhaled) | Non-small cell lung cancer (NSCLC) | gene therapy | Phase 2 |
| KB801 | Neurotrophic keratitis (NK) | gene therapy | Phase 1 |
| KB407 | Cystic fibrosis (CF) | gene therapy | Phase 1 |
| KB408 | Alpha-1 antitrypsin deficiency (AATD) lung disease | gene therapy | Phase 1 |
| KB304 | Wrinkles of the décolleté (aesthetics) | gene therapy | Phase 1 |
| KB113 | Not specified | gene therapy | Pre-clinical |
Recent results and decisions
- Nov 2, 2026started Jeune Aesthetics expects to initiate a Phase 2 study of KB304 in 2027.
Jeune Aesthetics, Inc., a wholly owned subsidiary of the Company, expects to initiate a Phase 2 study of its lead program KB304 in 2027.
Filing - Oct 31, 2026positive KB113 demonstrated clinical regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome.
More than 80% of assessed BCC lesions showed investigator-assessed clinical regression.
Filing - Oct 1, 2026positive KB113 demonstrated regression in more than 80% of assessed BCC lesions in Gorlin syndrome patients.
more than 80% of assessed BCC lesions showed investigator-assessed clinical regression. Regression was observed in both injected and non-injected lesions, consistent with an abscopal effect.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.